ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pan-KRAS Inhibitor ERAS-4001

Also written as “ERAS-4001” and “ERAS-4001 in combination”.

Its studies are mostly in Neoplasm Metastasis, led by Erasca.

Furthest: phase 1, since Jun 6, 20251 company-led study, 1 open or runningNext primary completion: Aug 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Erasca11 open or runningphase 1since Jun 6, 2025Jun 6, 2025Aug 2028phase 1 · NCT07021898

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 6, 2025First study: phase 1 study in Neoplasm MetastasisFirst studyNCT07021898 · 200 planned · United States

Ahead

  1. Aug 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT07021898

TargetBeta

KRAS →read by rule
“An orally bioavailable inhibitor that targets the oncogenic KRAS wild-type (WT) and various KRAS mutant forms, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07021898Neoplasm Metastasis · United States1RecruitingAug 2028200

How it is read

Names in the registry

  • “ERAS-4001”, 1 entry
  • “ERAS-4001 in combination”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.